Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Letter from Dr. Kadlec to the American Correctional Association

Dear American Correctional Association,

In November 2020, the U.S. Food and Drug Administration issued Emergency Use Authorizations (EUAs) for two monoclonal antibody therapies for use in high-risk patients with mild-to-moderate COVID-19. These outpatient treatments, if given early in the course of illness, can prevent hospitalizations, reduce strain on the U.S. Healthcare System, and save lives.

The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (HHS/ASPR) has implemented a new federal program for the allocation of these monoclonal antibodies called the Special Projects for Equitable and Efficient Distribution (SPEED). The goal of SPEED is to assist states in identifying non-hospital facilities that serve priority populations and are able and willing to administer these treatments. For more information on SPEED, see: https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Pages/SPEED.aspx.

SPEED is now rolling out a program to support direct allocation of monoclonal antibodies to state and local correctional facilities for us in eligible inmates. HHS/ASPR is excited to partner with the American Correctional Association to increase awareness about SPEED and encourage member organizations to participate.

To learn more about the monoclonal antibodies and assess if a correctional facility is prepared to administer them, please review the below links:


If a correctional facility (and/or healthcare system partner) is prepared to administer these monoclonal antibodies and is interested in receiving direct allocations through SPEED, please contact covidtix@hhs.gov.

Sincerely,
Dr. Robert Kadlec, MD, MTM&H, MS
Assistant Secretary for Preparedness and Response

  • This page last reviewed: April 16, 2021